Servier
Servier to Seek FDA, EMA Approvals for Vorasidenib in IDH-Mutant Glioma
The firm plans to submit data from the Phase III INDIGO study to regulators in the US and Europe by the end of 2023 and in early 2024, respectively.
The firm plans to submit data from the Phase III INDIGO study to regulators in the US and Europe by the end of 2023 and in early 2024, respectively.